Genetics and Genomics Digital Forum Nov 2022

  • Register
    • Regular Member - Free!
    • Early Career Member - Free!
    • Resident/Clinical Fellow Member - Free!
    • Postdoctoral Fellow Member - Free!
    • Graduate Student Member - Free!
    • Undergraduate Student Member - Free!
    • Emeritus Member - Free!
    • Life Member - Free!
    • Trainee Member - Free!
    • Nonmember - $74

A Two-Day Interactive Event Brought to You by ASHG hosted on November 15 & 16, 2022.

Please review the available agenda.

  • Contains 1 Component(s)

    This interactive workshop is intended for anyone interested in learning how to impute genotypes and to use the imputed genotypes, highlighting recent reference panels, including the multi-ancestry panel from the TOPMed program and a specialized HLA panel.

    Genotype imputation is a key component of modern genetic association studies. The Michigan Imputation Server has thus far helped > 8,500 researchers from around the world to impute > 80M human genomes. This interactive workshop is intended for anyone interested in learning how to impute genotypes and to use the imputed genotypes, highlighting recent reference panels, including the multi-ancestry panel from the TOPMed program and a specialized HLA panel. 

    A brief overview of imputation and the server will be followed by demonstrations and exercises, including: 

    1) quality control and preparation of genetic data for use on the MIS with a special focus on diverse ancestries, chromosome X, and the HLA region; 

    2) tracking runs and use of the application program interface for larger jobs; 

    3) downloading data from the MIS and preparing data for genetic analysis; 

    4) performing a GWAS using imputed data and interpreting results, taking into account imputation quality; 

    5) using the additional features, such as the polygenic risk score calculation. 

    We encourage participants to ask specific questions about their own projects. Workshop materials, including slides and example data sets, will be made available before the workshop and will remain online at the MIS website. We expect that this workshop will enable participants to generate high-quality imputed data sets and to effectively analyze them.

    Christian Fuchsberger

    Eurac Research

    Sebastian Schönherr

    Medical University of Innsbruck

    Xueling Sim

    National University of Singapore

    Lukas Forer

    Medical University of Innsbruck

    Saori Sakaue

    Broad Institute

    Albert Smith

    University of Michigan

  • Contains 1 Component(s) Recorded On: 11/15/2022

    This session will feature 3 plenary talks presented at ASHG 2022 plus live Q&A and panel discussion for each

    This session will feature 3 plenary talks presented at ASHG 2022. After each 15-minute talk there will be a 20-minute discussion session with additional panelists invited by the speaker, which will include Q&A from the audience.

    Moderator: Kiran Musunuru, MD, PhD, MPH, ML

    Speakers:

    1. Hardip Patel, PhD: Australia's National Centre for Indigenous Genomics enabling the inclusion of First Nations peoples in genomics
      1. Panelists: Alex Brown, Bastien Llamas 
    2. Rebecca Torene, PhD: Systematic analysis of nonsense-mediated decay escaping protein-truncating variants in 97,728 clinical exomes identifies new Mendelian disease genes
      1. Panelists: Scott Myers, Kevin Mitchell, Francisca Millan
    3. Lingyan Chen, PhD: Novel therapeutic target discovery using circulating proteins in up to 42,000 UK Biobank participants through systematic Mendelian randomization and genetic colocalization
      1. Panelists: Joanna Howson, Cyrielle Maroteau, Lina Cai

    Hardip Patel, PhD

    Bioinformatics Lead, National Centre for Indigenous Genomics

    The Australian National University

    Dr. Hardip Patel is a mid-career bioinformatics and genomics researcher with expertise in large scale genomics and molecular biology research. As the Bioinformatics Lead for the National Centre for Indigenous Genomics (NCIG) and a member of National Indigenous Genomics Network, he is responsible for implementing genomics data infrastructure & analytical platforms to enable precision medicine. His research focuses on developing and using innovative computational biology and bioinformatics techniques to assemble genomes and detect variations using population-scale genomic data. He has co-authored 50 research publications (2500+ citations; 22 h-index).

    Rebecca Torene, PhD

    Associate Director of Genomics Research

    GeneDx-Sema4

    Dr. Rebecca Iskow Torene is Associate Director of Genomics Research at GeneDx-Sema4, a diagnostics company specializing in rare diseases. Her research focuses on improving genetics-based diagnostics through innovative bioinformatics and data science strategies. Dr. Torene received her PhD in genetics from Emory University and completed both her postdoctoral research and MMSc in biomedical informatics from the Harvard Medical School. She currently resides in the Washington, DC area. 

    Lingyan Chen, PhD

    Senior Research Scientist at Genetics Centre of Excellence

    Novo Nordisk Research Centre Oxford

    Dr. Lingyan Chen is a Senior Research Scientist at Human Genetics Centre of Excellence at Novo Nordisk Research Centre Oxford (NNRCO).  She obtained her PhD degree from King’s College London and did her PostDoc research in University of Cambridge where she obtained strong skills in Statistical Data Analysis, Population Genetics and Functional Genetics of complex diseases and published high impact research papers Her primary research interest is to investigate potential causal molecules (i.e. transcriptome, proteome, and metabolome) for CMDs using genomics and other-comics data applying statistical genetic methodologies, such as Mendelian randomization (MR), to inform future therapeutic targets. 

  • Contains 1 Component(s)

    Topic-based rooms you can join to network and interact with other attendees!

    This session will feature a variety of topic-based rooms you can join to network and interact with other attendees! 

    There will be a  breakout room for each of the following scientific themes, each with a moderator to guide the conversation: 

    • Clinical, Basic and Population Research: Mendelian Phenotypes
      • Moderator: Rose Yang, PhD, MPH, NCI/NIH
    • Clinical, Basic and Population Research: Complex Traits
      • Moderator: Marina DiSteafano, PhD
  • Contains 1 Component(s) Recorded On: 11/15/2022

    Twelve new 5-minute poster talks, not presented at ASHG 2022, including Q&A time for each.

    Join this session to see 12 live poster talks, featuring all new content that was not presented at ASHG 2022. Each rapid-fire poster talk will be 5 minutes, followed by a brief Q&A with the presenter.

    Moderator: Andrew Marderstein, PhD

    Speakers: 

    • Whole Exome Sequencing revealed spectrum of mutations associated with different myopathy in clinically suspected DMD patients of Bangladesh, presented by Tamannyat Binte Eshaque, M.Sc. Contact this speaker
    • ANO7 alters prostate cell mitochondrial gene expression and metabolism, presented by Nasrin Sultana, MS Contact this speaker
    • Polygenic scoring and causal inference of posttraumatic stress disorder using electronic health records highlights association with cardiovascular and respiratory traits, presented by Gita Pathak, PhD Contact this speaker
    • Multiomic association studies and finemapping prioritises WDR6 and immune pathways to be associated with anorexia nervosa, presented by Danielle Adams, BS/BA Contact this speaker
    • The utility of whole exome sequencing in atypical cases of heterogeneous neurological disorders, presented by Zafar Ali, PhD 
    • A recessive variant in TFAM causes mtDNA depletion associated with primary ovarian insufficiency, seizures, intellectual disability and hearing loss, presented by Farid Ullah, PhD 
    • Identification of Hypomorphic SEL1L-HRD1 ER-associated Degradation Variants in Infants, presented by Huilun (Helen) Wang, PhD Contact this speaker
    • Comprehensive characterization of genetic influences on plasma metabolome in a pediatric cohort, presented by Sek Won Kong, MD Contact this speaker
    • 300 Billion Associations - Genetic architecture of 2,071 phenotypes in 658,582 individuals of diverse ancestry in the VA Million Veteran Program, presented by Anurag Verma, PhD Contact this speaker
    • CRISPR-Cas9 depletion of high expression genes in human fibroblast samples increases the diagnostic potential for rare disease, presented by Rosario Corona, PhD Contact this speaker
    • Deep convolutional and conditional neural networks for large-scale genomic data generation, presented by Burak Yelman, PhD Contact this speaker
    • Fundamental limitations on the transferability of polygenic risk scores across human populations, presented by Kaiqian Zhang, MS

    Speakers: 

    • Tamannyat Binte Eshaque, MS
    • Nasrin Sultana, MS
    • Gita Pathak, PhD
    • Danielle Adams, BS/BA
    • Zafar Ali, PhD
    • Farid Ullah, PhD
    • Huilun Wang, PhD
    • Sek Won Kong, MD
    • Anurag Verma, PhD
    • Rosario Corona, PhD
    • Burak Yelmen, PhD
    • Kaiqian Zhang, MS
  • Contains 1 Component(s)

    The workshop will provide an interactive, hands-on experience for participants and familiarize the audience with the latest bioinformatics tools that facilitate automation of genetic annotation and pharmacogenomics (PGx) annotation for large-scale, electronic health record-linked health care systems.

    Digitalization of patient medical charts in the form of electronic health record (EHR) promotes precision medicine, which promises to be inclusive of a broad view of a person’s care. Disease genetics and pharmacogenomics (PGx) contributes to the success of precision medicine by providing genetic insights from preemptive care and disease diagnosis to drug prescribing recommendation. However, integrating genomics with EHR-linked health care systems is challenging. The ever increasing scale of EHR-linked health care systems ensues an increasing need for automated, computational annotation of genetic information to support fast-paced clinical decision making. This workshop will introduce several bioinformatics tools that facilitate automatic, computable annotation of genetic information. Computable representation of genetic variants is one bottleneck for accurate genetic curation and automatic annotation in analyses following clinical genetic tests. 

    The first part of the workshop will focus on the Variation Representation Specification (VRS, pronounced “verse”), a recently published standard of the Global Alliance for Genomics and Health for the computable representation of biomolecular variation. VRS allows precise and federatable identification of genetic variants for downstream disease annotations and PGx annotations in EHR-linked health care systems. The associated VRSATILE (“versatile”) framework provides additional tools for representation of variation in computable genomic knowledge exchange. Exemplary applications of VRSATILE include knowledge and evidence retrieval across databases (e.g., functional and clinical databases) and computable representation of PGx variants. The second part of the workshop focuses on automating PGx annotations using PharmCAT (Pharmacogenomics Clinical Annotation Tool). PharmCAT is able to digest genetic information from VCFs, infer PGx named alleles and phenotypes, and generate detailed reports for clinical decision support. The capability of PharmCAT to automate PGx annotation makes it possible to translate clinical genetic test results to clinical decisions and actions at the scale of EHR-linked, large-scale health care systems. The workshop will provide an interactive, hands-on experience for participants and familiarize the audience with the latest bioinformatics tools that facilitate automation of genetic annotation and PGx annotation for large-scale, EHR-linked health care systems.

    Michelle Whirl-Carrillo

    Dr. Whirl-Carrillo is Co-Principal Investigator and Director of the Pharmacogenomics Knowledge Base (PharmGKB), Co-Director of Informatics for the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Co-Investigator of the Pharmacogenomics Clinical Annotation Tool (PharmCAT). Her research interests include the translation of human genome sequencing data to pharmacogenomic-based therapeutic recommendations. She has 20 years of experience in the field, working collaboratively on many projects and serving on multiple advisory boards. Michelle received her PhD in Biophysics from Stanford University and her SB in Biology from MIT.

    Alex Wagner

    Dr. Wagner is an Assistant Professor at The Steve and Cindy Rasmussen Institute for Genomic Medicine (IGM) at Nationwide Children’s Hospital, and in the Departments of Pediatrics and Biomedical Informatics at the Ohio State University College of Medicine. His research is focused on the development of tools and standards for advancing precision medicine and our knowledge of genomic alterations in cancers. Dr. Wagner recently received a Genomic Innovator award from the National Human Genome Research Institute (NHGRI) in support of his work to develop computable applications of genomic knowledge in clinical practice and is a co-lead of the BRIDGE Center Standards Core for the NIH Bridge2AI program. He is a strong advocate for open science resources and initiatives, including his service as director of the international Variant Interpretation for Cancer Consortium (VICC; cancervariants.org), co-leader of the Variant Representation group of the Global Alliance for Genomics and Health (ga4gh.org), and member of the HGVS Variation Nomenclature Committee.

    Dr. Wagner has co-developed several precision medicine web tools, including the Drug-Gene Interaction Database (www.dgidb.org), the database of Clinical Interpretations of Variants in Cancer (CIViC; www.civicdb.org), and the VICC meta-knowledgebase (search.cancervariants.org). His research continues to explore new models and tools to address the challenges of variation representation, including his work as a lead designer of the GA4GH Variation Representation Specification (vrs.ga4gh.org) and the VICC Gene Fusion specification (fusions.cancervariants.org).

    Katrin Sangkuhl

    Dr. Katrin Sangkuhl is a senior scientific curator at PharmGKB in the Department of Biomedical Data Science at Stanford University. She contributes to the development, maintenance, and application of the Pharmacogenomics Clinical Annotation Tool (PharmCAT) and is actively involved in the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Pharmacogene Variation (PharmVar) Consortium.

    Binglan Li

    Postdoctoral Scholar

    Dr. Binglan Li is a postdoctoral Scholar in Dr. Teri Klein's lab since late 2020. She is interested in genomic medicine and promoting the implementation of pharmacogenomics in clinical care through the development of tools, such as PharmCAT (Pharmacogenomics Clinical Annotation Tool). Her doctoral projects focused on understanding the genetic architecture of complex human traits and translational biomedical research using ‘omics data integrative methods and electronic health records. Binglan obtained a BS from Fudan University, China, and a PhD from the University of Pennsylvania.

    Teri Klein

    Dr. Teri Klein is the Principal Investigator for the PharmGKB and Professor of Biomedical Data Science and Medicine at Stanford University. Dr. Klein is also the Co-Principal Investigator for CPIC (Clinical Pharmacogenetics Implementation Consortium) and PharmCAT. She was recruited from the University of California, San Francisco faculty and was the Director of the PharmGKB since it began in April 2000 until September 2019. Teri received her PhD in medical information sciences from the University of California, San Francisco and a BA in biology/chemistry from the University of California, Santa Cruz. Prior to becoming the director of the PharmGKB in 2000, Dr. Klein was an Associate Adjunct Professor at UCSF.

    Marylyn Ritchie

    Dr. Marylyn Ritchie is a Professor of Genetics, Director of the Institute for Biomedical Informatics, Director of the Center for Translational Bioinformatics Institute for Biomedical Informatics, and Associate Director of the Center for Precision Medicine at the University of Pennsylvania School of Medicine. Dr. Ritchie is a statistical and computational geneticist with a focus on understanding the genetic architecture of complex human diseases. She has expertise in developing novel bioinformatics tools for complex analysis of big data in genetics, genomics, and clinical databases, particularly in the area of Pharmacogenomics. She is the co-PI of PharmCAT.

    Mark Woon

    Mark Woon is the co-technical lead at PharmGKB and PharmCAT and has been with PharmGKB since 2001. He received his BSE in computer science from Princeton University. Prior to working on the PharmGKB project, Mark worked for Sun Microsystems and Netscape Communications.

    Wesley Goar

    Dr. Wesley Goar is a Senior Bioinformatics Scientist in the Wagner Lab at Nationwide Children’s Hospital in Columbus, Ohio. He obtained his undergraduate degree in Molecular Biology from Brigham Young University and his doctorate degree in Computational Genomics from the University of Iowa. During his graduate training he performed bioinformatics analyses of rare inherited eye diseases using genome, exome, panel, and RNA-sequencing technologies. After graduating, he managed the bioinformatics team for Immortagen Inc, performing cancer diagnostic reports for patients in China. He currently works on the standardization of variant data and the automation of variant assessment.

    Kori Kuzma

    Kori Kuzma graduated from The Ohio State University with a bachelor’s degree in Computer Science and Engineering. At the Institute for Genomic Medicine, she develops and deploys web applications for the analysis and interpretation of genomic variants.

    Katie Stahl

    Katie Stahl does full-stack development for the Wagner lab at Nationwide Children’s Hospital, working with research staff to develop open-source bioinformatics applications for efficient data analysis and visualization. Katie received her degree in Computer Science with a minor in Mathematics from Capital University.

    James Stevenson

    James Stevenson is a software developer in the Wagner Lab at Nationwide Children’s Hospital. He holds a bachelor’s degree in Political Science and Philosophy from the University of Puget Sound and is completing a master’s degree in Computer Science from the Georgia Institute of Technology. His research interests include applications of machine learning techniques in clinical medicine.

    Karl Keat

    Karl Keat is a PhD candidate in Genomics and Computational Biology at the University of Pennsylvania, where he works in the labs of Dr. Marylyn RItchie and Dr. Dokyoon Kim. His research focuses on pharmacogenomics and mutli-omics data integration for improving drug response prediction.

  • Contains 1 Component(s)

    Game Changed. Redefining Genomic Sequencing with HiFi Long Reads on Revio

    Advanced registration is required for this event. Please register now at this site. Registration is quick and free, and you can register anytime!

    Upon registration, you will receive a confirmation email with your unique join link. Please join the session from your emailed confirmation link. It may take a few minutes for your link to be emailed to you, so we encourage you to register early so you don’t miss the start of the session.

    If you have any trouble registering, please reach out to exhibits@ashg.org.


    PacBio Logo

    Title: Game Changed. Redefining Genomic Sequencing with HiFi Long Reads on Revio

    Join us as three industry experts present on their work demonstrating a new gold standard in genomic and translational research with PacBio HiFi sequencing. Featuring presentations on methylation, complex medically relevant genes (CMRG) in dark regions, and SNM1/2 calling, we will take you on an exploration of what is possible and how you could apply their approaches to your own research and future breakthroughs.

    • Speakers: 
    • Edd Lee, Director, Human Genomics, PacBio (Introduction) 
    • Warren Cheung, Bioinformatics Manager, Genomic Medicine Center, Children’s Mercy Hospital (Methylation) 
    • Fritz Sedlazeck, PhD, Associate Professor, Human Genome Sequencing Center, Baylor College of Medicine (Dark Regions) 
    • Xiao Chen, PhD, Principal Bioinformatics Scientist, PacBio (SNM1/2 Calling) 


    *By registering for and attending this session, you consent to share your contact information with the sponsor of this session. Please view the disclaimer tab for more information.

    By clicking on the registration and event links for this session, please recognize you are being directed to a webinar or registration form from the sponsoring company where you may be asked to submit your contact information in order to attend the sponsored session. By completing the registration form and/or by attending an industry event, your information will be collected by the sponsoring company, and you may be contacted regarding your session attendance and future interest in the company’s products or services. 

     
    The hosting of any promotional material, links, or sessions on the ASHG website or the ASHG Learning Center does not indicate an endorsement by ASHG of the products or services promoted, the company, or the claims made. ASHG does not sell, rent, or share member contact information. Any information you choose to share will be shared with the company directly, and you may request to be removed from their mailing lists at any time. 

  • Contains 1 Component(s)

    Current guidelines from the American College of Medical Genetics and Genomics and Association of Molecular Pathology (ACMG/AMP) are primarily designed for interpretation of genetic variants that impact protein-coding regions of the genome. We formed an expert panel to design recommendations for how to adapt the ACMG/AMP guidelines for variants in other genomic contexts (Ellingford et al. 2021)

    Background: Current guidelines from the American College of Medical Genetics and Genomics and Association of Molecular Pathology (ACMG/AMP) are primarily designed for interpretation of genetic variants that impact protein-coding regions of the genome. We formed an expert panel to design recommendations for how to adapt the ACMG/AMP guidelines for variants in other genomic contexts (Ellingford et al. 2021).

    Aim of the workshop: The aim of this interactive workshop is to outline key aspects of the recommendations and detail practical steps towards using the guidance in clinical settings. Users will utilize case examples to develop hands-on working knowledge of the modified guidelines. By the end of the workshop attendees will be able to:

    • Understand changes to ACMG/AMP rules. Describe the key adaptations to the ACMG/AMP rules that are needed to effectively curate non-coding region variants and detail the extra considerations applicable when applying individual ACMG/AMP rules.
    • Access datasets to define relevant non-coding regions. Understand how to access and interpret the key data and tools required to interpret non-coding region variants. Specifically, you will be familiar with how to access epigenetic data to define non-coding regulatory elements, and will know which in silico tools can be used to predict the pathogenicity of different variant types.
    • Perform variant classification for a range of non-coding region variants. Know how to practically approach interpretation of non-coding region variants in your own setting having worked through a series of example curations

    Expected prior knowledge / experience: This workshop is aimed at clinical scientists and genetics professionals with an active role in clinical variant interpretation. You will have a working knowledge of the current ACMG/AMP guidelines for small sequence variants.

    Format: The workshop will be 90 minutes in length, with approximately 30 minutes spent on each of the three main aims outlined above. The first 30 minutes will be a talk on the background behind and the key aspects of the recommendations. The second 30 minutes will be a demonstration on how to access the tools and resources required to curate non-coding region variants, and the final 30 minutes will be an interactive work-through of example variant curations.

    Reference: Ellingford JM et al. medRxiv. Dec 2021. doi:10.1101/2021.12.28.21267792v1

  • Contains 2 Component(s) Recorded On: 11/16/2022

    Curating the Human Genome to Advance Early Identification of Rare Diseases: Meeting the Needs of Newborn Sequencing

    The recording of this session is now available. Please view in the Content tab. 


    Genomenon Logo

    Title: Curating the Human Genome to Advance Early Identification of Rare Diseases: Meeting the Needs of Newborn Sequencing

    The most critical challenge to making newborn sequencing a reality is genomic variant interpretation. Current approaches of interpreting variants one-by-one are impractical when it comes to screening a mostly healthy newborn population with whole genome sequencing. A radically different approach is needed to hit the time, cost, and throughput objectives for newborn screening of whole genomes. 

    In this live discussion and demonstration, industry experts will show how a comprehensive, pre-curated list of causative variants can be used to rapidly screen for rare diseases and how a unique combination of AI-driven genomic technology and expert scientific review has emerged as the best and most viable way to curate the entire human genome. 

    The speakers will describe Genomenon’s contributions to the BeginNGS™ initiative at the Rady Children’s Institute for Genomic Medicine, and how pre-curated classifications for every variant found in the scientific literature will be used to screen against over 450 genetic diseases at birth. They will then show how variant classification and supporting evidence is presented in the Mastermind® Genomic Search Engine to enable rapid assessment and identification of newborns at risk for developing a rare disease. 

    The session will include a Q&A session around the implications of this technology on the future of rare disease screening and diagnosis. 

    You will learn: 

    • How a unique balance of AI and expert review creates a solid foundation of high-quality evidence to understand the genetic basis of a targeted disease 
    • How the integration of data from the scientific literature with commonly used variant databases like ClinVar streamline accurate and timely diagnoses for patients 
    • How this approach is being used to comprehensively access and classify every variant in the human genome, starting with newborn sequencing applications 

    Speakers:

    • Mark Kiel, MD, PhD, Chief Scientific Officer, Genomenon 
    • Brittnee Jones, PhD, Director of Customer Success, Genomenon


    *By registering for and attending this session, you consent to share your contact information with the sponsor of this session. Please view the disclaimer tab for more information.

    By clicking on the registration and event links for this session, please recognize you are being directed to a webinar or registration form from the sponsoring company where you may be asked to submit your contact information in order to attend the sponsored session. By completing the registration form and/or by attending an industry event, your information will be collected by the sponsoring company, and you may be contacted regarding your session attendance and future interest in the company’s products or services. 

     
    The hosting of any promotional material, links, or sessions on the ASHG website or the ASHG Learning Center does not indicate an endorsement by ASHG of the products or services promoted, the company, or the claims made. ASHG does not sell, rent, or share member contact information. Any information you choose to share will be shared with the company directly, and you may request to be removed from their mailing lists at any time. 

  • Contains 1 Component(s) Recorded On: 11/16/2022

    This session will feature 3 plenary talks presented at ASHG 2022 plus live Q&A and panel discussion for each

    This session will feature 3 plenary talks presented at ASHG 2022. After each 15-minute talk there will be a 20-minute discussion session with additional panelists invited by the speaker, which will include answering questions from the audience.

    Moderator: Erica Davis, PhD

    Speakers:

    1. Endrina Mjuica, MD: Characterizing 54 type-2 diabetes candidate genes using CRISPR/Cas9, in vivo imaging and deep learning in zebrafish larvae 
      1. Panelists: Marcel den Hoed (Group Leader), Christoph Metzendorf (Researcher), Eugenia Mazzaferro (PhD student)
    2. Scott Younger, MD, PhD: Rapid and scalable preclinical evaluation of personalized antisense oligonucleotides using organoids derived from rare disease patients
      1. Panelists: None
    3. Yi Ding, MS: Polygenic score performance varies across the continuum of genetic ancestry in all human populations
      1. Panelists: Bogdan Pasaniuc

    Endrina Mujica, MD

    PhD student at Marcel den Hoed's Lab

    Uppsala University

    Endrina Mujica is a PhD student at Marcel den Hoed’s research lab at Uppsala University, Sweden. She obtained her under graduate medical training from the University of Zulia in her home town of Maracaibo, Venezuela. During her medical training, she performed genetic screens to characterize allelic variants associated to metabolic alterations as part of “The Maracaibo city metabolic syndrome prevalence study”. She was then awarded an Erasmus scholarship to pursue the International Master in Innovative Medicine, an Erasmus Joint Master degree. This included courses at both Uppsala University and University of Groningen. Currently, she is doing her PhD studies at Uppsala University at Marcel den Hoed’s lab. The lab is focused on characterizing candidate genes for metabolic diseases using in vivo imaging and deep learning in zebrafish larvae. They have developed systematic and large-scale screens for the study of diabetes, obesity, cardiovascular, non-alcoholic fatty liver and kidney disease. These efforts aim to improve our understanding of disease etiology and help prioritize genes for further in-depth characterization. 

     

    Scott Younger, MD, PhD

    Director of Disease Gene Engineering

    Children's Mercy Research Institute

    Dr. Scott Younger is the Director of Disease Gene Engineering within the Genomic Medicine Center at Children's Mercy Kansas City. He has extensive experience working with high-throughput sequencing-based screening technologies and is leading efforts to dissect the molecular mechanisms through which rare genetic variants identified in patients at Children's Mercy lead to disease. Dr. Younger came to Children's Mercy from the Broad Institute of MIT and Harvard where his group worked on the development of CRISPR-based screening methods. He completed his postdoctoral studies at Harvard University as an American Cancer Society Fellow. He holds a Ph.D. in cell and molecular biology from UT Southwestern Medical Center. He also received an M.S. in biotechnology from the University of Texas at San Antonio and a B.S.I. in bioinformatics from Baylor University.

    Yi Ding, MS

    PhD candidate in Bioinformatics

    UCLA

    Yi Ding is a fifth-year PhD student in Bioinformatics from UCLA advised by Dr. Bogdan Pasaniuc. She is interested in Bayesian Inference and the probabilistic modeling of complex genetic architecture. Currently, she is working with the UCLA-ATLAS Biobank to investigate the evaluation of individual-level polygenic score performance and the interpretation of polygenic scores across diverse genetic ancestries. Prior to UCLA, she obtained her Master’s degree in Biostatistics from Harvard T.H. Chan School of Public Health and her Bachelor’s degree in Biotechnology from Zhejiang University in China.  

  • Contains 1 Component(s)

    Topic-based rooms you can join to network and interact with other attendees!

    This session will feature a variety of topic-based breakout rooms you can join to network and interact with other attendees! There will be one room for each of the following themes: 

    • Public Outreach & Education
    • Social Implications & Ethics
    • Career Transitions/Working in Industry

    ASHG volunteer leaders who are experts in these areas will be leading the conversation in each space. Moderators for this session include:

    • Arvind Kothandaraman, MA
    • Justin Ideozu, PhD
    • Stephanie Kraft, JD
    • Kyle Brothers, MD, PhD
    • Andrew Landstrom, MD, PhD
    • Benjamin Kang, PhD
    • Honey Reddi, PhD